ClinicalTrials.gg
CompletedNCT03155503SUVN-911Updated May 29, 2018

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects

A Phase 1 interventional study of SUVN-911 and Placebo in Depressive Disorder, Major, sponsored by Suven Life Sciences Limited. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-29.

Sponsored by Suven Life Sciences Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2018, 8 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
685th of 1,323
64 · median 70
Started
2017
with 64 others
Phase 1
103 of 1,500
15 open now
Registered
889th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 685th largest by enrollment of the 1,323 interventional ones that give a count, is one of 65 that started in 2017, is one of 103 in phase 1, and was the 889th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, conventional, double-blind, placebo-controlled, single-center clinical study comprised of 2 segments (Segment 1 and Segment 2) in which single and multiple doses of SUVN-911 or placebo will be orally administered to healthy male subjects to evaluate the safety, tolerability, and pharmacokinetic profile.

Read the detailed description

This is a single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of SUVN-911 administered orally once a day to healthy male subjects. The study will be conducted under double-blind conditions.

The primary objectives are to evaluate the safety and tolerability of SUVN-911 following oral administration of single or multiple ascending doses and estimate the maximum tolerated dose of SUVN-911, if possible.

The secondary objectives are to evaluate the single and repeat dose plasma and urine pharmacokinetics of SUVN-911 following oral administration of single and multiple ascending doses in healthy male subjects.

03

Conditions studied

  • Depressive Disorder, Major

Keywords

  • SUVN-911
  • Depression
  • single dose
  • multiple dose
  • alpha4 beta2 receptor
  • first in human
  • safety
  • pharmacokinetics
  • tolerability
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male aged 18 to 45 years with a (BMI) between 18 and 30 kg/m2, (inclusive).

Exclusion criteria

Exclusion Criteria:

  • Standard exclusion criterion for Phase 1 clinical trial in healthy subjects:

    • History of any disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate.
    • History or presence of gastro intestinal (GI), hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs as judged by Investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Active comparator
    Single ascending dose

    Single dose of SUVN-911 or placebo in healthy male subjects

    Drug: SUVN-911 · Drug: Placebo

  • Active comparator
    Multiple ascending dose

    Multiple doses of SUVN-911 or placebo in healthy male subjects

    Drug: SUVN-911 · Drug: Placebo

Interventions

  • DrugSUVN-911

    Oral Tablet

  • DrugPlacebo

    Oral Tablet

06

What researchers measure

Primary outcomes

  1. ECG (Electrocardiogram)

    electrocardiogram outcomes

    Time frame: Range of Day 1-17

  2. Vital signs

    blood pressure determination

    Time frame: Range of Day 1-17

  3. C-SSRS (Columbia Suicidal Severity Rating Scale)

    Columbia Suicidal Severity Rating in multiple doses

    Time frame: Range of Day 1-17

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC)

    Plasma concentration

    Time frame: Day 1 and Day 14

  2. Maximum observed concentration (Cmax)

    Maximum concentration observed

    Time frame: Day 1 and Day 14

  3. Time to reach maximum concentration (Tmax)

    Determination of maximum time taken to reach the maximum concentration

    Time frame: Day 1 and Day 14

  4. Terminal half-life (t½)

    Elimination rate

    Time frame: Day 1 and Day 14

07

Study locations

1 site
  • QuintilesIMS Phase 1 Services, LLC
    Kansas City, Kansas 66211, United States
08

References and documents

Publications

  • Nirogi R, Benade V, Goyal VK, Pandey SK, Mohammed AR, Shinde A, Dogiparti D, Ravula J, Jetta S, Palacharla VRC. Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (alpha4beta2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects. Clin Drug Investig. 2022 Sep;42(9):747-762. doi: 10.1007/s40261-022-01189-9. Epub 2022 Aug 13. PubMed 35963959 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Mar 2018, 9 months.

Of 40 industry-sponsored phase 1 interventional studies under Depressive Disorder, Major, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 12. This study's 9 months is above that.

Counting every sponsor, half of 88 studies reached it within 16 months; a quarter within 5 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2017
First posted
May 16, 2017
StartActual
May 22, 2017
Primary completionActual
Mar 7, 2018
CompletionActual
Mar 14, 2018
Last update
May 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03155503
Lead sponsor
Suven Life Sciences Limited
Responsible party
Sponsor
First posted
May 16, 2017
Start date
May 22, 2017
Primary completion
Mar 7, 2018
Completion
Mar 14, 2018
Last update
May 29, 2018

Study contacts

Barbara Lomeli
principal investigator · Quintiles, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion